Recent studies have suggested that statins, the inhibitors for 3-hydroxy-3-methyglutaryl (HMG)-CoA reductase in the mevalonate pathway, exhibit anti-inflammatory effects. However, the immune modulatory effects of statins on the differentiation of CD4
Introduction

Activated CD4
+ T cells differentiate into at least three distinct effector subsets as defined by their patterns of cytokine production (1) (2) (3) (4) . T h 1 cells produce IFN-c and lymphotoxin and play a critical role in protective immunity against intracellular pathogens (1) (2) (3) (4) . T h 2 cells produce IL-4, IL-5 and IL-13 and are essential for the expulsion of parasites (1) (2) (3) (4) . Newly identified IL-17-producing T cells (T h 17 cells), which produce IL-17A, IL-17F and IL-22, play a role in host defense against invading extracellular pathogens and are also implicated in the pathogenesis of a number of autoimmune diseases (1) (2) (3) (4) . On the other hand, Foxp3
+ regulatory T cells (Tregs) actively restrain the inflammatory response induced by effector T cells and dampen a wide spectrum of immune responses including autoimmune diseases (5, 6) . Furthermore, it is suggested that T h 17 cells and Tregs are reciprocally regulated during differentiation (7) (8) (9) (10) .
Statins inhibit 3-hydroxy-3-methyglutaryl (HMG)-CoA reductase, which catalyzes the conversion of HMG-CoA to L-mevalonate (11, 12) , and have been used as cholesterollowering agents all over the world (11, 12) . In addition, recent studies have demonstrated that statins exert additional beneficial effects, independent of lipid-lowering effect, that have been ascribed to their modulating effect on the immune system (11, 12) . For example, it has been reported that atorvastatin reduces the duration and severity of active and passive experimental autoimmune encephalomyelitis (EAE) (13, 14) . In human, oral administration of simvastatin has been shown to exhibit a beneficial effect in patients with multiple sclerosis in a small open-label trial (15) . Atorvastatin has also been shown to lower disease scores in patients with rheumatoid arthritis (16) . Regarding the mechanisms of immune modulatory effects of statins, early studies have shown that statins inhibit autoimmune diseases through the suppression of T h 1 cell differentiation (13, 14) . However, Zhang et al. (17) have recently shown that simvastatin inhibits the expression of IL-17A and retinoic acid-related orphan nuclear hormone receptor C, a transcription factor that controls IL-17A production in human CD4
+ T cells, suggesting that statins may also inhibit the differentiation of T h 17 cells.
Inhibition of HMG-CoA reductase results in the reduction of all mevalonate pathway products (18, 19) . Mevalonate is a precursor not only for the synthesis of cholesterol but also for the synthesis of isoprenoids, including geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP) (18, 19) . Protein farnesylation is catalyzed by farnesyltransferase (FTase), whereas protein geranylgeranylation is catalyzed by geranylgeranyltransferase (GGTase) (18, 19) . Recently, it has been demonstrated that the inhibition of Ras farnesylation and RhoA geranylgeranylation is essential for preventing T h 1 cell-mediated development of EAE (20) . However, the immune modulatory effects of statins on the differentiation of T h 17 cells and Tregs and their underlying mechanisms are still largely unknown.
To address these issues, we examined the effect of simvastatin and inhibitors for protein farnesylation and geranylgeranylation on the differentiation of T h 17 cells and Foxp3
+ T cells. We found that simvastatin and GGTase I inhibitor GGTI-298, but not FTase inhibitor FTI-277, inhibited the differentiation of T h 17 cells. Noteworthy, we also found that simvastatin and GGTI-298 but not FTI-277 enhanced the differentiation of Foxp3 + CD4 + T cells. Moreover, GGTI-298 but not FTI-277 induced the expression of SOCS3 and inhibited IL-6-induced signal transducers and activators of transcription (STAT)3 phosphorylation. Our results indicate that the balance between the differentiation of T h 17 cells and Foxp3
+
CD4
+ T cells is regulated by protein geranylgeranylation via the inhibition of SOCS3 expression.
Methods
Mice
BALB/c mice and SCID mice on a BALB/c background were purchased from Charles River Laboratories (Kanagawa, Japan). Ovalbumin peptide (OVA) 323-339-specific TCR transgenic mice (DO11.10 mice) on a BALB/c background were described previously (21) . All mice were housed in microisolator cages under specific pathogen-free conditions. Animal procedures used in this study were approved by the Chiba University Animal Care and Use Committee.
Reagents
Four milligrams of simvastatin (Merck & Co. Inc., Rahway, NJ, USA) was dissolved in 0.1 ml of 100% ethanol, added with 0.15 ml of 0.1 N NaOH and activated by heating for 2 h at 50°C. The solution was subsequently neutralized to pH 7.2 with HC1, brought up to a volume of 1 ml with distilled water and frozen in aliquots. GGTase I inhibitor GGTI-298 and FTase inhibitor FTI-277 were purchased from Calbiochem (San Diego, CA, USA) and were dissolved in DMSO according to the manufacturer's instruction. Antibodies to CD3e (145-2C11), CD25 (PC61), CD28 (37.51), IL-4 (11B11), IL-6 (MP5-20F3), IFN-c (XMG1.2) and IL-6Ra (D7715A7) were purchased from BD Biosciences (San Diego, CA, USA). Antibodies to Foxp3 (FJK-16s), glucocorticoid-induced tumor necrosis factor receptor (GITR) (DTA-1) and GP130 (KGP130) were purchased from eBioscience (San Diego, CA, USA). Murine IL-6 and human transforming growth factor-b (TGF-b) were purchased from PeproTech Inc. (Rocky Hill, NJ, USA) and R&D Systems (Minneapolis, MN, USA), respectively.
Cell culture
CD4
+ CD25 À T cells were negatively sorted from the spleen of BALB/c mice by magnetic cell sorting using a cocktail of biotin-conjugated antibodies against CD8a, B220, CD11b, CD25, CD49b, TCRcd and Ter-119 (Miltenyi Biotec, Sunnyvale, CA, USA) according to the manufacturer's instruction. In some experiments, naive CD4 + CD62L high T cells were purified by using a mouse CD4
+ CD62L + T cell isolation kit II (Miltenyi Biotec). The purity of cells was routinely >97% by FACS analysis. CD4
+ CD25 À T cells or CD4 + CD62L high T cells (1 3 10 6 cells ml
À1
) were stimulated with plate-bound anti-CD3e mAb (1 lg ml
) plus anti-CD28 mAb (2 lg ml
) in RPMI 1640 medium supplemented with 10% heat-inactivated FCS, 50 lM b-mercaptoethanol, 2 mM L-glutamine and antibiotics at 37°C. Where indicated, IL-6 (100 ng ml
), anti-IL-4 mAb (10 lg ml
) and anti-IFN-c mAb (10 lg ml
) were added to induce T h 17 cells (T h 17-polarizing condition), whereas TGF-b (1 ng ml
) was added to induce Tregs (Treg-inducing condition).
ELISA
The amounts of IL-17A in the culture supernatants were measured by the enzyme immunoassay using a murine IL-17 ELISA kit from BD Biosciences. The assays were performed in duplicate according to the manufacturer's instruction. The minimum significant value of the assay was 15 pg ml À1 of IL-17A.
Intracellular staining
Intracellular staining for IL-17A, IL-17F, IFN-c and Foxp3 was performed as described previously (22) .
Real-time PCR analysis
Total cellular RNA was extracted with ISOGEN solution (Nippon GENE Co., LTD, Tokyo, Japan). Reverse transcription was carried out using an iScript cDNA synthesis kit (BioRad, Hercules, CA, USA). TaqMan PCR for Foxp3, RORct and SOCS3 was performed using a standard protocol on ABI PRISM 7300 instrument (Applied Biosystems, Foster City, CA, USA) (22) . The levels of Foxp3, RORct and SOCS3 were normalized to the levels of b-actin.
Western blotting
CD4
+ CD25 À T cells were stimulated with plate-bound antiCD3e mAb plus anti-CD28 mAb in the presence or absence of GGTI-298 (5 lM) or FTI-277 (5 lM) for 24 h. The cells were cultured in fresh medium for 24 h and then stimulated with IL-6 (10 ng ml À1 ) for 10 min. Cells were then lysed with cell lysis buffer and the aliquot of lysates was applied for SDS-PAGE (23 ) with GGTI-298 (5 lM) or vehicle were added to the culture. Sixty hours later, cells were stained with anti-KJl-26 mAb, which recognizes DO11.10 TCR, and the frequency of non-dividing KJ1-26 + cells was assessed by FACS.
Colitis models
Freshly isolated CD4 + CD25 À T cells (4 3 10 5 cells per mouse) from BALB/c mice were injected intra-peritoneally to SCID mice as described previously (24) . Where indicated, CD4 + CD25 À T cells (4 3 10 5 cells per mouse) stimulated for 3 days with plate-bound anti-CD3e mAb plus anti-CD28 mAb in the presence of TGF-b (1 ng ml
À1
) with GGTI-298 (5 lM) or vehicle were co-injected to the mice. Weight changes were monitored daily. Six weeks later, histological analysis was performed and histological scores were evaluated as described previously (25) by a pathologist in a blinded manner.
Data analysis
Data are summarized as means 6 SDs. The statistical analysis of the results was performed by the unpaired t-test. P values <0.05 were considered significant.
Results
Simvastatin inhibits T h 17 cell differentiation
TGF-b and IL-6 cooperatively instruct the expression of the orphan nuclear receptor RORct, which in turn drives naive CD4 + T cells into T h 17 effector T cell subset that produces proinflammatory cytokines such as IL-17A, IL-17F and IL-22 (2-4). To determine whether statin inhibits the differentiation of murine T h 17 cells, we first examined the effect of simvastatin on the differentiation of IL-17A-producing CD4
+ T cells at single-cell levels. Splenic CD4 + T cells were stimulated with plate-bound anti-CD3 mAb plus anti-CD28 mAb (anti-CD3/ CD28 mAb) under T h 17-polarizing condition (IL-6, TGF-b, anti-IL-4 mAb and anti-IFN-c mAb) with indicated concentrations of simvastatin (0-2 lM) for 3 days and intracellular cytokine profiles for IL-17A versus IFN-c were evaluated. As shown in Fig. 1 (A) (upper panels), IL-17A-producing CD4 + T cells were markedly decreased by simvastatin in a dosedependent manner. CD4
+ T cells that produce IL-17F, another representative cytokine produced by T h 17 cells, were also decreased by simvastatin (data not shown). On the other hand, the numbers of IFN-c-producing CD4 + T cells (Fig. 1A) as well as the proliferative responses of CD4 + T cells (data not shown) were not significantly affected by simvastatin. IL-17A-producing CD4
+ T cells were decreased by simvastatin even when naive CD4 + CD62L high T cells were used as a source of CD4 + T cells (Fig. 1A , lower panels). Inhibition of IL-17A production by simvastatin was confirmed by measuring IL-17A levels in the supernatants of anti-CD3/CD28-stimulated CD4 + T cells (n = 5, P < 0.01) (Fig. 1B) . Consistent with the decreased production of IL-17A but not of IFN-c, the expression of RORct but not of T-bet was decreased in simvastatin-treated CD4
+ T cells (Fig. 1C) . Lovastatin, another representative statin, similarly inhibited IL-17A production and the expression of RORct (data not shown). Moreover, the addition of mevalonate reversed the inhibitory effects of simvastatin on the differentiation of IL-17A-producing CD4 + T cells (Fig. 1D ) and IL-17A production from anti-CD3/CD28-stimulated CD4 + T cells (n = 5, P < 0.01) (Fig. 1E) . These results suggest that simvastatin inhibits the differentiation of T h 17 cells through the inhibition of HMG-CoA reductase activity. + CD4 + T cells in a dose-dependent manner ( Fig. 2A) . In Treg-inducing condition, simvastatin increased the differentiation of Foxp3 + CD4 + T cells more strongly as compared with that under T h 17-polarizing condition ( Fig. 2A) . In addition, simvastatin enhanced the mRNA levels of Foxp3 in T h 17-polarizing condition and Treg-inducing condition (Fig. 2B) . In contrast, in the absence of TGF-b, regardless of the presence of IL-6, simvastatin did not induce the differentiation of Foxp3 + CD4 + T cells ( Fig. 2A) . These results indicate that simvastatin enhances the differentiation of Foxp3 + CD4 + T cells in the presence of TGF-b.
GGTase I inhibitor but not FTase inhibitor inhibits T h 17 cell differentiation
Mevalonate is a precursor not only for the synthesis of cholesterol but also for the synthesis of isoprenoids such as GGPP and FPP (18 (Fig. 3A) . In addition, GGTI-298 but not FTI-277 significantly decreased the levels of IL-17A in the culture supernatants in a dose-dependent manner (n = 5, P < 0.01) (Fig. 3B) . Moreover, although it has been shown that the inhibition of protein geranylgeranylation induces apoptosis in myeloma cells (26), we found that cell death was not significantly enhanced by GGTI-298 (5 lM) in CD4 + T cells (data not shown). On the other hand, GGTI-298 but not FTI-277 significantly increased the differentiation of Foxp3 + CD4 + T cells under T h 17-polarizing condition (Fig. 3A) . Real-time PCR analysis revealed that GGTI-298 increased the expression of Foxp3 mRNA but decreased the expression of RORct mRNA under T h 17-polarizing condition (Fig. 3C) . These results indicate that protein geranylgeranylation but not protein farnesylation is involved in the regulation of the balance between T h 17 cells and Foxp3 + CD4 + T cells. (Fig. 4B) . Furthermore, when CD4 + CD25 À T cells from DO11.10 mice were stimulated with OVA323-339 peptide presented on irradiated BALB/c splenocytes as antigen-presenting cells in the presence of TGF-b, GGTI-298 significantly enhanced the differentiation of Foxp3 + CD4 + T cells (Fig. 4C) , suggesting that the induction of Foxp3 + CD4 + T cells by GGTI-298 could be applicable to antigen-specific activation of CD4 + T cells. We also examined whether Foxp3 + CD4 + T cells developed in the presence of TGF-b and GGTI-298 functioned as Tregs using an in vitro co-culture assay in which CFSElabeled CD4 + CD25 À T cells from DO11.10 mice were used as responder cells. As expected, when DO11.10 CD4 +
GGTI-298 enhances TGF-b-induced differentiation of
CD25
À T cells were stimulated with OVA323-339 peptide in the presence of CD4 + CD25 À T cells from BALB/c mice that had been stimulated with anti-CD3/CD28 mAb for 3 days in the presence of TGF-b and vehicle, the number of nondividing DO11.10 CD4 + T cells was significantly increased as compared with control group (n = 5, P < 0.05) (Fig. 5B) . Importantly, when DO11.10 CD4 + CD25 À T cells were stimulated with OVA323-339 peptide in the presence of CD4 +
À T cells that had been stimulated with anti-CD3/CD28 mAb for 3 days in the presence of TGF-b and GGTI-298, the number of non-dividing DO11.10 CD4 + T cells was more significantly increased as compared with control group (n = 5, P < 0.01) (Fig. 5B) . As expected, CD4 + CD25 À T cells that had been stimulated with anti-CD3/CD28 mAb in the absence of TGF-b did not inhibit the cell division of responder cells (Fig. 5B) . These results suggest that Foxp3
cells developed in the presence of TGF-b and GGTI-298 have a suppressive activity against CD4
+ T cell proliferation in vitro.
We also examined the regulatory activity of Foxp3 + CD4 + T cells developed in the presence of TGF-b and GGTI-298 in vivo. We employed an autoimmune colitis model in which freshly isolated CD4 + CD25 À T cells from BALB/c mice were transferred to SCID mice. As described previously (24) , the mice injected with freshly isolated CD4 + CD25 À T cells alone (denoted as 'b') developed severe colitis (Fig. 6A) and exhibited a severe decrease in body weight (Fig. 6B) . When the mice were co-injected with freshly isolated CD4 + CD25 À T cells and CD4 + CD25 À T cells that had been stimulated with anti-CD3/CD28 mAb in the presence of TGF-b alone (denoted as 'c'), the severity of colitis and body weight loss was slightly decreased (Fig. 6A and B) . When the mice were co-injected with freshly isolated CD4 + CD25 À T cells and CD4 + CD25 À T cells that had been stimulated with anti-CD3/ CD28 mAb in the presence of TGF-b and GGTI-298 (denoted as 'd'), the severity of colitis and body weight loss was significantly decreased (n = 5, P < 0.05) (Fig. 6A and B) . These results suggest that Foxp3 + CD4 + T cells developed in the presence of TGF-b and GGTI-298 function as Tregs in the autoimmune colitis model.
GGTI-298 inhibits IL-6-induced STAT3 phosphorylation in CD4
+ T cells IL-6-STAT3 pathway, together with TGF-b, induces RORct expression and IL-17A production in CD4 + T cells (3, 4) . In addition, it has been demonstrated that IL-6-STAT3 pathway opposes Foxp3 expression and inducible Treg differentiation in a cell-intrinsic manner (3, 4) . To address the mechanisms by which GGTI-298 decreases T h 17 cell differentiation and enhances Foxp3
+ CD4 + T cell differentiation, we examined IL-6-induced STAT3 phosphorylation in GGTI-298-treated CD4 + T cells. CD4 + CD25 À T cells were stimulated with anti-CD3/CD28 mAb in the presence of GGTI-298, FTI-277 or vehicle for 24 h, rested for 24 h in fresh medium and then stimulated with IL-6 for 10 min. As shown in Fig. 7(A) , It has recently been shown that statins up-regulate the expression of SOCS3, a potent inhibitor of STAT3 signaling (27) and T h 17 cell differentiation (28) , in murine macrophages (29) and in human peripheral blood monocytes (17) . We therefore examined the expression of SOCS3 in GGTI-298-treated CD4 + T cells. Interestingly, the expression of SOCS3 was significantly increased in GGTI-298-treated CD4 + T cells as compared with FTI-277-or vehicle-treated CD4 + T cells (Fig. 7B) . On the other hand, the expressions of IL-6R components, IL-6Ra and gp130, were similar among these cells (Fig. 7C) . Taken together, these results suggest that the inhibition of IL-6-STAT3 signaling by SOCS3 may be involved in the inhibition of T h 17 cell differentiation and the induction of
Discussion
In this study, we show that protein geranylgeranylation regulates the balance between the differentiation of T h 17 cells and Foxp3 + CD4 + T cells. We found that simvastatin inhibited the differentiation of T h 17 cells under T h 17-polarizing condition by the inhibition of HMG-CoA reductase activity (Fig. 1) . In contrast, simvastatin enhanced the differentiation of Foxp3 + CD4 + T cells under T h 17-polarizing and Treg-inducing conditions (Fig. 2) . We also found that GGTI-298 but not FTI-277 mimicked the effects of simvastatin (Figs 3 and 4) , indicating that the inhibition of protein geranylgeranylation is responsible for the reduced differentiation of T h 17 cells and the enhanced differentiation of Foxp3 + CD4 + T cells. Moreover, we found that Foxp3 + CD4 + T cells developed in the presence of TGF-b and GGTI-298 functioned as Tregs in in vitro suppression assay (Fig. 5) as well as in an autoimmune colitis model (Fig. 6) . Finally, GGTI-298 induced SOCS3 expression and inhibited IL-6-induced STAT3 phosphorylation in CD4 + T cells (Fig. 7) . Taken together, these results indicate that the balance between the differentiation of T h 17 cells and Foxp3 + Tregs is regulated by protein geranylgeranylation through the inhibition of SOCS3 expression.
We show that simvastatin inhibits the differentiation of T h 17 cells (Fig. 1) . Regarding the effect of statins on helper T cell differentiation, early studies have demonstrated that atorvastatin suppresses the differentiation of pro-inflammatory T h 1 cells and then inhibits autoimmune disease models (13, 14) . On the other hand, we found that simvastatin inhibited the differentiation of T h 17 cells at the concentrations that did not inhibit the differentiation of T h 1 cells (Fig. 1) . Because it is now apparent that T h 17 cells play important roles in the pathogenesis of autoimmune disease models including EAE (2-4), our data suggest that the inhibition of T h 17 cell differentiation by statins may also be involved in the beneficial effect of statins on the autoimmune disease models.
Importantly, we show that GGTI-298, a GGTase I inhibitor, but not FTI-277, an FTase inhibitor, mimics the inhibitory effect of simvastatin on the differentiation of T h 17 cells (Fig. 3) , suggesting that the inhibition of protein geranylgeranylation but not farnesylation is involved in the decreased differentiation of T h 17 cells by simvastatin treatment. On the other hand, it has been reported that FTI-277, but not GGTI-298, inhibits the differentiation of T h 1 cells (20) . Therefore, it is indicated that although both T h 17 cells and T h 1 cells are suppressed by statins, the different isoprenylation pathways are involved in statin-mediated suppression of T h 17 cell and T h 1 cell differentiation.
We also show that simvastatin enhances the differentiation of Foxp3 + CD4 + T cells (Fig. 2) . Consistent with this finding, it has recently been reported that simvastatin treatment increases the number of CD25 + CD4 + T cells in peripheral blood of hyperlipidemic patients (30) . We also found that GGTI-298, but not FTI-277, mimicked the effect of simvastatin on Foxp3 + CD4 + T cell differentiation ( Figs 3  and 4) , suggesting that the inhibition of protein geranylgeranylation but not farnesylation is involved in the enhanced differentiation of Foxp3 + CD4 + T cells by simvastatin treatment. Foxp3 has been shown to be the most reliable lineage marker for Tregs and to be sufficient for exhibiting their regulatory activity (5, 6) . Indeed, we found that Foxp3
+ T cells developed in the presence of TGF-b and GGTI-298 expressed higher levels of CD25 and GITR as compared with Foxp3 À CD4 + T cells (Fig. 5 ) and exhibited regulatory functions on the proliferation of naive CD4 + T cells in vitro (Fig. 5) . Foxp3 + CD4 + T cells developed in the presence of TGF-b and GGTI-298 also exhibited regulatory functions on the development of autoimmune colitis in vivo (Fig. 6) , in which T h 1 cells (31) (33, 34) . Regarding the mechanisms by which inhibition of protein geranylgeranylation results in the decreased T h 17 cell differentiation, we found that GGTI-298 inhibited IL-6-induced phosphorylation of STAT3 (Fig. 7) . In addition, we found that GGTI-298 induced the expression of SOCS3, a potent inhibitor of STAT3 signaling (27) and the differentiation of T h 17 cells (28) , in CD4 + T cells (Fig. 7) . Moreover, in the preliminary study, we found that GGTI-298 did not significantly inhibit the differentiation of T h 17 cells in T cell-specific SOCS3-deficient mice (CD4-cre/SOCS3 flox/flox mice), suggesting that SOCS3 plays (Fig. 4) . Together, these findings suggest that inhibition of protein geranylgeranylation induces SOCS3 expression and then attenuates T h 17 cell differentiation through the inhibition of STAT3 signaling, which is accompanied by the reciprocal enhancement of Foxp3
The mechanisms underlying the up-regulation of SOCS3 expression by GGTI-298 remains unclear. Protein prenylation is a post-translational modification that either 15-carbon farnesyl or 20-carbon geranylgeranyl isoprenoid is linked via a thioether bond to specific cysteine residues of proteins that share a carboxyl-terminal CAAX motif (where C is cysteine residue that becomes prenylated, A is an aliphatic amino acid and X is any amino acid) (18) . Protein farnesylation is catalyzed by FTase, whereas protein geranylgeranylation is catalyzed by GGTase (18) . FTase prefers CAAX sequences where X is methionine, serine, cysteine or glutamine, whereas GGTase I prefers leucine or isoleucine at the X position (18) . Representative proteins that have been shown to be catalyzed by GGTase I are Rac1, RhoA and Rap1a (18) . However, our preliminary experiments showed that a Rho-associated kinase inhibitor Y-27632 did not affect the expression of SOCS3 in CD4 + T cells, suggesting that RhoA might not be involved in this process. Furthermore, a previous study using RAW264.7 macrophages has shown that the up-regulation of SOCS3 by statin is not affected by inhibitors of protein kinase A, protein kinase C, mitogen-activated protein/ERK kinase, p38 MAPK, Raf, Ras or tyrosine kinases (29) . Identification of geranylgeranylated proteins that induce the expression of SOCS3 and regulate the balance between T h 17 cells and Foxp3 + CD4 + T cells is an important issue to be solved in future.
In conclusion, we have shown that inhibition of protein geranylgeranylation decreases the differentiation of T h 17 cells and enhances the differentiation of Foxp3 + CD4 + T cells. Although further studies are required to address the underlying mechanisms, our data suggest that a small molecule inhibitor for protein geranylgeranylation such as statins can be an attractive candidate for the treatment of autoimmune diseases. The usage of ex vivo-generated Foxp3 + CD4 + T cells with inhibitors of protein geranylgeranylation may also be an alterative approach for the treatment of autoimmune diseases.
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